Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson's Disease?

Tatou Iseki1, Yuzuru Imai1,2, Nobutaka Hattori1,2,3,4,5

  • 1Department of Neurology, School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Biomolecules
|January 21, 2023
PubMed

Insights

Leucine-rich repeat kinase 2 (LRRK2) mutations are linked to Parkinson's disease (PD). This review explores LRRK2's role in glial cells, suggesting it impacts neurodegeneration through inflammation and organelle dysfunction.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Leucine-rich repeat kinase 2 (LRRK2) is a key gene in familial Parkinson's disease (PD).
  • LRRK2 kinase phosphorylates Rab small GTPases, but its precise role in PD pathogenesis remains unclear.
  • Non-autonomous neurodegeneration, involving glial cell dysfunction, is an emerging PD mechanism.

Purpose of the Study:

  • To review the proposed functions of LRRK2 in glial cells.
  • To discuss LRRK2's involvement in the pathomechanisms of Parkinson's disease.

Main Methods:

  • Literature review of molecular and pathological studies on LRRK2.
  • Analysis of LRRK2's role in astrocyte and microglia function.
  • Examination of LRRK2's impact on organelle dynamics and inflammation.

Main Results:

  • LRRK2 is implicated in regulating lysosomal and organelle dynamics within glial cells.
  • LRRK2 dysfunction in glia may contribute to neuroinflammation.
  • Evidence suggests LRRK2's role in non-autonomous neurodegeneration.

Conclusions:

  • LRRK2 plays a significant role in glial cell function.
  • Dysregulation of LRRK2 in glia is a potential contributor to Parkinson's disease pathogenesis.
  • Further research into LRRK2 in glial cells may reveal novel therapeutic targets for PD.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
644
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Glial Cells01:04

Glial Cells

Overview
88.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
331